
February 20, 2024
RegMed Investors’ (RMi) pre-open: navigating the uncertain inflation economic derivative financial markets
February 16, 2024
RegMed Investors (RMi) Closing Bell: the cell and gene therapy closed barely positive after a bumpy session
February 16, 2024
RegMed Investors’ (RMi) pre-open: a ripple effect soon to be in motion
February 15, 2024
RegMed Investors (RMi) Closing Bell: riding the bull
February 15, 2024
RegMed Investors’ (RMi) pre-open: got a broom?
February 15, 2024
RegMed Investors (RMi) Research Note: Prime Medicine (PRME) Prices 19million share offering at $6.25
February 14, 2024
RegMed Investors (RMi) Closing Bell: yippee-kai-yay
February 14, 2024
RegMed Investors’ (RMi) pre-open: earnings’ reality check
February 13, 2024
RegMed Investors (RMi) Closing Bell: CPI infused dominoes topple the cell and gene therapy sector
February 13, 2024
RegMed (RMI) Research Note: CRISPR Therapeutics (CRSP) Registered Direct Offering (RDO) $280 M offering priced at $71.50
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors